Ongoing Gaps in the Hepatitis C Care Cascade during the Direct-Acting Antiviral Era in a Large Retrospective Cohort in Canada: A Population-Based Study

Ana Maria Passos-Castilho,Donald G. Murphy,Karine Blouin,Andrea Benedetti,Dimitra Panagiotoglou,Julie Bruneau,Marina B. Klein,Jeffrey C. Kwong,Beate Sander,Naveed Z. Janjua,Christina Greenaway

DOI: https://doi.org/10.3390/v16030389

2024-03-02

Viruses

Abstract:To achieve hepatitis C virus (HCV) elimination, high uptake along the care cascade steps for all will be necessary. We mapped engagement with the care cascade overall and among priority groups in the post-direct-acting antivirals (DAAs) period and assessed if this changed relative to pre-DAAs. We created a population-based cohort of all reported HCV diagnoses in Quebec (1990–2018) and constructed the care cascade [antibody diagnosed, RNA tested, RNA positive, genotyped, treated, sustained virologic response (SVR)] in 2013 and 2018. Characteristics associated with RNA testing and treatment initiation were investigated using marginal logistic models via generalized estimating equations. Of the 31,439 individuals HCV-diagnosed in Quebec since 1990 and alive as of 2018, there was significant progress in engagement with the care cascade post- vs. pre-DAAs; 86% vs. 77% were RNA-tested, and 64% vs. 40% initiated treatment. As of 2018, a higher risk of not being RNA-tested or treated was observed among individuals born 1965 [hazard ratio (HR); 95% CI; 1.35 (1.16–1.57)], those with material and social deprivation [1.21 (1.06–1.38)], and those with alcohol use disorder [1.21 (1.08–1.360]. Overall, non-immigrants had lower rates of RNA testing [0.76 (0.67–0.85)] and treatment initiation [0.63 (0.57–0.70)] than immigrants. As of 2018, PWID had a lower risk of not being RNA tested [0.67 (0.61–0.85)] but a similar risk of not being treated, compared to non-PWID. Engagement in the HCV care cascade have improved in the post-DAA era, but inequities remain. Vulnerable subgroups, including certain older immigrants, were less likely to have received RNA testing or treatment as of 2018 and would benefit from focused interventions to strengthen these steps.

virology

What problem does this paper attempt to address?

The paper aims to address issues in the hepatitis C virus (HCV) care continuum and evaluate the progress of the care continuum in Quebec, Canada, before and after the era of direct-acting antivirals (DAAs).

Specifically:
1. **Research Background**: To eliminate hepatitis C as a public health threat, a high proportion of the population needs to complete all steps of the HCV care continuum (diagnosis, treatment, etc.). Canada has signed on to the World Health Organization (WHO) goal of eliminating hepatitis C by 2030.
2. **Research Objectives**: To map the care continuum for all populations and key populations (such as drug users, immigrants, etc.) before and after the introduction of DAAs, and to assess changes in the care continuum among these populations.
3. **Key Findings**: From 2013 to 2018, the proportion of those who received RNA testing after HCV diagnosis increased from 77% to 86%, and the proportion who received treatment increased from 40% to 64%. Despite overall improvements, inequalities persist in certain vulnerable groups (such as older immigrants), indicating the need for further interventions to strengthen these areas.